--- title: "Jasper Therapeutics (JSPR) news: reverse split and class action" url: "https://aibio.space/companies/jasper-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "JSPR reverse split, class action, going concern and offering news: Jasper Therapeutics receives Nasdaq minimum bid price notice, has until November 30, 2026." --- JSPR Jasper Therapeutics, Inc. NASDAQ · United States # Jasper Therapeutics (JSPR) news JSPR reverse split, class action and going concern news Legal · 2026-10-15 ## [Jasper Therapeutics faced Oct 15 hearing on motion to dismiss briquilimab class action](https://aibio.space/news/jasper-therapeutics-faced-oct-15-hearing-motion-dismiss-briquilimab/) Defendants: Jasper and unnamed current and former officers; derivative suits are captioned against Martell and others. A motion to dismiss was set for hearing October 15, and no ruling is reported. ## Latest Jasper Therapeutics news 1. 2026-10-07 Mergers [Jasper Therapeutics offers $0.324 per warrant to buy back up to 12,345,707 warrants](https://aibio.space/news/jasper-therapeutics-offers-0-324-warrant-buy-back-up-12-345-707/) Jasper Therapeutics will pay $0.324 in cash per warrant for up to 12,345,707 warrants, about $4.0 million if all are tendered, and the offer runs until November 6, 2026. 2. 2026-06-09 Listings [Jasper Therapeutics receives Nasdaq minimum bid price notice, has until November 30, 2026](https://aibio.space/news/jasper-therapeutics-receives-nasdaq-minimum-bid-price-notice-has-until/) Nasdaq notified Jasper (JSPR) on June 3, 2026 that its voting common stock closed below $1.00 for thirty consecutive business days. The notice has no immediate effect on trading; a reverse stock split is among the options named. 3. 2025-09-18 Financings [Jasper Therapeutics prices $30 million offering of stock and warrants](https://aibio.space/news/jasper-therapeutics-prices-30-million-offering-stock-warrants/) Jasper priced 11,670,707 shares and 675,000 pre-funded warrants, each with a common warrant, at $2.43, for about $30 million before costs. The prospectus also discloses an unresolved trial investigation and a going concern warning. 4. 2025-07-09 Distress [Jasper Therapeutics cuts workforce by about 50% and halts other programs to extend cash runway](https://aibio.space/news/jasper-therapeutics-cuts-workforce-about-50-percent-halts-other/) Jasper's board approved a corporate reorganization on July 8, 2025. The company will focus on briquilimab in chronic urticaria, expects $1.8 million to $2.2 million in severance cash costs, and its chief medical officer is leaving. ## Jasper Therapeutics at a glance - **Ticker**: JSPR - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $7.3 million ### Related companies - [Enliven Therapeutics](https://aibio.space/companies/enliven-therapeutics/) NASDAQ: ELVN - [Sana Biotechnology](https://aibio.space/companies/sana-biotechnology/) NASDAQ: SANA - [Conexeu Sciences](https://aibio.space/companies/conexeu-sciences/) NASDAQ: CNXU - [Curis](https://aibio.space/companies/curis/) NASDAQ: CRIS - [SKYTECH ORION GLOBAL CORP.](https://aibio.space/companies/skytech-orion-global/) OTC: SKTG - [FibroBiologics](https://aibio.space/companies/fibrobiologics/) NASDAQ: FBLG - [Aspira Women's Health](https://aibio.space/companies/aspira-women-s-health/) OTC: AWHL - [Instil Bio](https://aibio.space/companies/instil-bio/) NASDAQ: TIL ### Also on NASDAQ - [Dare Bioscience](https://aibio.space/companies/dare-bioscience/) DARE - [Harrow](https://aibio.space/companies/harrow/) HROW - [Gyre Therapeutics](https://aibio.space/companies/gyre-therapeutics/) GYRE - [Rein Therapeutics](https://aibio.space/companies/rein-therapeutics/) RNTX - [TransMedics Group](https://aibio.space/companies/transmedics/) TMDX - [Atara Biotherapeutics](https://aibio.space/companies/atara-biotherapeutics/) ATRA ## Jasper Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$63.1 million](https://www.sec.gov/Archives/edgar/data/1788028/000121390026036426/) | [$55.8 million](https://www.sec.gov/Archives/edgar/data/1788028/000121390026036426/) | | Net income (loss) | [-$75.8 million](https://www.sec.gov/Archives/edgar/data/1788028/000121390026036426/) | [-$71.3 million](https://www.sec.gov/Archives/edgar/data/1788028/000121390026036426/) | | Cash from operations | [-$77.2 million](https://www.sec.gov/Archives/edgar/data/1788028/000121390026036426/) | [-$62.6 million](https://www.sec.gov/Archives/edgar/data/1788028/000121390026036426/) | | Cash and equivalents | [$28.7 million](https://www.sec.gov/Archives/edgar/data/1788028/000121390026089592/) | [$71.6 million](https://www.sec.gov/Archives/edgar/data/1788028/000121390026036426/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $7.3 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Jasper Therapeutics Did Jasper Therapeutics do a reverse stock split? Our latest story on this, dated Jun 9, 2026: "Jasper Therapeutics receives Nasdaq minimum bid price notice, has until November 30, 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/jasper-therapeutics-receives-nasdaq-minimum-bid-price-notice-has-until/). Is there a class action against Jasper Therapeutics? Our latest story on this, dated Oct 15, 2026: "Jasper Therapeutics faced Oct 15 hearing on motion to dismiss briquilimab class action". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/jasper-therapeutics-faced-oct-15-hearing-motion-dismiss-briquilimab/). Has Jasper Therapeutics issued a going-concern warning? Our latest story on this, dated Sep 18, 2025: "Jasper Therapeutics prices $30 million offering of stock and warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/jasper-therapeutics-prices-30-million-offering-stock-warrants/). Has Jasper Therapeutics raised money recently? Our latest story on this, dated Sep 18, 2025: "Jasper Therapeutics prices $30 million offering of stock and warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/jasper-therapeutics-prices-30-million-offering-stock-warrants/). What is the ticker symbol of Jasper Therapeutics? Jasper Therapeutics, Inc. trades under the ticker JSPR on NASDAQ. Where is Jasper Therapeutics listed? Jasper Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Jasper Therapeutics? The SEC Central Index Key (CIK) for Jasper Therapeutics, Inc. is 1788028. Its filings are on SEC EDGAR. How many shares does Jasper Therapeutics have outstanding? 33,274,561 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Jasper Therapeutics listed under? Our directory records Jasper Therapeutics, Inc. under United States. What does Jasper Therapeutics do? Our directory classifies Jasper Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Jasper Therapeutics? The ISIN recorded for Jasper Therapeutics, Inc. is US4718712023. Does aibio.space cover Jasper Therapeutics? aibio.space lists Jasper Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Jasper Therapeutics incorporated? SEC records list its state or country of incorporation as DE. Is Jasper Therapeutics profitable? Jasper Therapeutics, Inc. reported a net loss of $75.8 million for the fiscal year ended Dec 31, 2025, and used $77.2 million of cash in operations, per its annual report to the SEC. How much does Jasper Therapeutics spend on research and development? $63.1 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Jasper Therapeutics Members talk about Jasper Therapeutics (JSPR). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Jasper Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-10-19 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1788028/000121390026110751/ea0307636-02.htm) 2. 2026-10-09 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1788028/000121390026108482/ea0307636-01.htm) 3. 2026-10-07 Financings Offered to buy back its own securities. SEC Form SC TO-I. [Source](https://www.sec.gov/Archives/edgar/data/1788028/000121390026107397/ea0307912-sctoi_jasper.htm) 4. 2026-10-07 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1788028/000121390026107402/ea030792501ex99-1.htm) 5. 2026-10-05 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1788028/000121390026106651/ea0307484-8k_jasper.htm) 6. 2026-09-24 Listings Filed to remove its shares from exchange listing. SEC Form 25-NSE. [Source](https://www.sec.gov/Archives/edgar/data/1788028/000135445726000914/xslF25X02/primary_doc.xml) 7. 2026-09-04 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1788028/000121390026097572/ea0302959-02.htm) 8. 2026-08-24 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1788028/000121390026093145/ea0302959-01.htm) 9. 2026-07-17 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.01,3.02,5.02,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1788028/000121390026078887/ea029822901ex99-1.htm) 10. 2026-07-16 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1788028/000121390026078781/ea029831601ex99-1.htm) 11. 2026-06-09 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1788028/000121390026066782/ea0294010-8k_jasper.htm) 12. 2026-06-01 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1788028/000121390026063157/ea029290901ex99-1.htm) 13. 2026-03-30 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1788028/000121390026036426/ea0282128-10k_jasper.htm) 14. 2025-09-18 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1788028/000121390025089025/ea0257862-424b5_jasper.htm) 15. 2025-07-09 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1788028/000121390025062194/ea024839401ex99-1_jasper.htm) 16. 2025-03-19 Financings Reported a financing. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1788028/000121390025025077/ea0234730-s3_jaspertherap.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:JSPR on TradingView](https://www.tradingview.com/symbols/NASDAQ-JSPR/). ## SEC filings and registration - **SEC name**: Jasper Therapeutics, Inc. - **CIK**: 1788028 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: JSPR (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 2200 BRIDGE PKWY SUITE #102, REDWOOD CITY, CA, 94065 - **Phone**: 6505491400 - **Shares outstanding**: 33,274,561 as of 2026-08-10 (10-Q filed 2026-08-14) - **Former names**: Amplitude Healthcare Acquisition Corp ### Recent filings (8-K and 6-K are the company's own announcements) - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1788028/000121390026110751/ea0307636-02.htm) filed 2026-10-19 - [8-K](https://www.sec.gov/Archives/edgar/data/1788028/000121390026109587/ea0308657-8k_jasper.htm) filed 2026-10-15 - [S-3](https://www.sec.gov/Archives/edgar/data/1788028/000121390026109479/ea0308420-s3_jasper.htm) filed 2026-10-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1788028/000121390026107402/ea0307925-8k_jasper.htm) filed 2026-10-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1788028/000121390026106651/ea0307484-8k_jasper.htm) filed 2026-10-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1788028/000121390026104101/ea0306856-8k_jasper.htm) filed 2026-09-28 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1788028/000121390026097572/ea0302959-02.htm) filed 2026-09-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1788028/000121390026093979/ea0303509-8k_jasper.htm) filed 2026-08-26 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001788028), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Jasper Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker JSPR, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Jasper Therapeutics, Inc. - **Ticker**: JSPR - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US4718712023 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-JSPR/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/jasper-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Jasper Therapeutics (JSPR) news: reverse split and class action", 2026-10-31, https://aibio.space/companies/jasper-therapeutics/